<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00580151</url>
  </required_header>
  <id_info>
    <org_study_id>04-101</org_study_id>
    <secondary_id>IFFA</secondary_id>
    <nct_id>NCT00580151</nct_id>
  </id_info>
  <brief_title>The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children</brief_title>
  <acronym>clonidine</acronym>
  <official_title>The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some of the children who suffer acute burn injury do not have adequate pain and anxiety
      management with the current regimen of scheduled opiates (morphine) and benzodiazepines
      (lorazepam). Other children have significant side effects or contraindications, such as
      constipation or over sedation, when taking these medications. Clonidine is known to reduce
      the need for morphine in the management of postoperative pain. The addition of clonidine to
      the pharmacological treatment of burn wound pain offers a possible adjunct to the standard
      opiate and benzodiazepines regimen. Clonidine has been used in children in both on a
      short-term basis (such as postoperative pain management) and on a long-term basis (such as
      the treatment of attention deficit hyperactivity disorder (ADHD)). This study tests the
      hypothesis that clonidine in a dose of 5 ug/kilo every 8 hours will be a useful adjunct to
      the management of pain and anxiety in the acutely burned child. All children will be treated
      by protocol with morphine (0.03mg/kilo) q4hr prn pain and lorazepam (0.03 mg/kilo) q 4 hours
      prn anxiety. In addition, after informed consent is obtained the children will be randomized
      to the addition clonidine or placebo. Pain and anxiety will be assessed using standard
      instruments blind to the medication being used on a daily basis Also the total dose of
      morphine and lorazepam during the 10 days of added clonidine or placebo will be recorded..
      The pain rating, anxiety ratings, total morphine dose, and total lorazepam dose will be
      compared between the placebo and clonidine groups with a Student's t test. Once the blind is
      broken the child will be allowed to remain on the clonidine if it is beneficial. The second
      year of the grant will expand the age groups down to younger children and also begin to gain
      information about the effect of clonidine on the hypermetabolic state secondary to burn
      injury.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to no response from PI to IRB
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Reduction</measure>
    <time_frame>Average of the 10 days</time_frame>
    <description>The scale name is &quot;FACES&quot; (Faces Pain Rating Scale). Subjects were asked &quot;rate your WORST PAIN today&quot; (0 = no pain at all, 1-4 = mild pain, 5-6 = moderate pain, 7-9 = severe pain, 10 = excruciating pain). The Faces Pain Rating Scale should be collected every day and then averaged.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety Reduction</measure>
    <time_frame>Average of the 10 days</time_frame>
    <description>The &quot;Fear Thermometer&quot; measures how much fear subject is currently having. (0=None, 1= A little bit, 2= Some, 3= A lot, 4= Very, very much). The average of daily Value for 10 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Pain</condition>
  <condition>Anxiety</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clonidine</intervention_name>
    <description>3-5 microgram per kilogram every 6 hours for 10 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 dose every 6 hours</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pain not controled by morphine

          -  Anxiety not controled by lorazepam

          -  Burn injuries of 20% or greater

          -  Burn type: scald or flame

        Exclusion Criteria:

          -  Small burn injury

          -  Electrical burns
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter J. Meyer III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Medical Branch at Galveston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Hospital for Children; Shriners Burns Hospital</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2007</study_first_posted>
  <results_first_submitted>February 8, 2013</results_first_submitted>
  <results_first_submitted_qc>February 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain not controled by morphine</keyword>
  <keyword>Anxiety not controled by lorazepam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clonidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruited in the medical clinic. Recruitment occured between 11/10/04-7/16/05.</recruitment_details>
      <pre_assignment_details>All participants were eligible to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental Group</title>
          <description>clonidine : 3-5 microgram per kilogram every 6 hours for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>placebo : 1 dose every 6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental Group</title>
          <description>clonidine : 3-5 microgram per kilogram every 6 hours for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>placebo : 1 dose every 6 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="3.2"/>
                    <measurement group_id="B3" value="7.8" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Reduction</title>
        <description>The scale name is &quot;FACES&quot; (Faces Pain Rating Scale). Subjects were asked &quot;rate your WORST PAIN today&quot; (0 = no pain at all, 1-4 = mild pain, 5-6 = moderate pain, 7-9 = severe pain, 10 = excruciating pain). The Faces Pain Rating Scale should be collected every day and then averaged.</description>
        <time_frame>Average of the 10 days</time_frame>
        <population>Determined by the number of patients recruited.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>clonidine : 3-5 microgram per kilogram every 6 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>placebo : 1 dose every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Reduction</title>
          <description>The scale name is &quot;FACES&quot; (Faces Pain Rating Scale). Subjects were asked &quot;rate your WORST PAIN today&quot; (0 = no pain at all, 1-4 = mild pain, 5-6 = moderate pain, 7-9 = severe pain, 10 = excruciating pain). The Faces Pain Rating Scale should be collected every day and then averaged.</description>
          <population>Determined by the number of patients recruited.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".73" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety Reduction</title>
        <description>The &quot;Fear Thermometer&quot; measures how much fear subject is currently having. (0=None, 1= A little bit, 2= Some, 3= A lot, 4= Very, very much). The average of daily Value for 10 days.</description>
        <time_frame>Average of the 10 days</time_frame>
        <population>Patients analyzed were all patients consented.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental Group</title>
            <description>clonidine : 3-5 microgram per kilogram every 6 hours for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>placebo : 1 dose every 6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety Reduction</title>
          <description>The &quot;Fear Thermometer&quot; measures how much fear subject is currently having. (0=None, 1= A little bit, 2= Some, 3= A lot, 4= Very, very much). The average of daily Value for 10 days.</description>
          <population>Patients analyzed were all patients consented.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".76" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental Group</title>
          <description>clonidine : 3-5 microgram per kilogram every 6 hours for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>placebo : 1 dose every 6 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No Adverse Events Recorded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Walter Meyer, M.D.</name_or_title>
      <organization>University of Texas-Galveston</organization>
      <phone>409-770-6718</phone>
      <email>wmeyer@utmb.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

